|
|
By John Giantsidis and Maria Papademetris, CyberActa, Inc.
To begin an initial communication with stakeholders, the FDA has released two discussion papers for consideration: Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products and Artificial Intelligence in Drug Manufacturing. In them, the agency identifies current and potential areas for AI adoption as well as key questions that the FDA is requesting input on. The deadline for public comments is August 9, 2023.
|